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LETTER TO THE EDITOR
Vincristine alleviates adriamycin-induced 
nephropathy through stabilizing actin 
cytoskeleton
Lei Yin1, Youying Mao1, Hejie Song2,3, Ye Wang2,3, Wei Zhou1 and Zhen Zhang2,3* 
Abstract 
Antimicrotubule agent vincristine (VCR) has long been known as an alternative treatment for frequent relapse 
nephrotic syndrome and steroid-dependent nephrotic syndrome (SDNS). However, the mechanism is unknown. 
Here we found that VCR at a dosage much lower than that as an antimicrotubule agent can alleviate adriamycin 
(ADR)-induced proteinuria and podocyte foot process effacement. In cultured podocytes, VCR prevents ADR-induced 
actin fiber disorganization. In both in vitro and in vivo models, VCR suppresses ADR-induced overexpression of α3β1 
integrin and focal adhesion kinase (FAK). These data suggest that VCR may relieve ADR-induced nephropathy through 
inhibiting injury-induced activation of integrin outside-in signaling to prevent actin cytoskeleton remodeling. Hence, 
our work reveals a novel role of VCR in regulating actin fiber assembly and provides first evidence on the therapeutic 
mechanism of VCR on nephrotic syndrome.
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Background
Minimal change nephrotic syndrome (MCNS) is a com-
mon renal disease in childhood. Although about 90% of 
children with MCNS respond to prednisone treatment, 
nearly 30% of them have frequent relapses or develop 
steroid-dependent nephrotic syndrome. Steroid toxicity 
following repeated steroid treatment demands alternative 
treatments in those patients [1]. However, current corti-
costeroid-sparing agents prescribed for children with fre-
quent relapse nephrotic syndrome and SDNS have their 
own shortcomings, such as high frequent relapses after 
levamisol or mycophenolic acid discontinuing, risk for 
infertility after repeated courses of alkylating agents and 
nephrotoxicity of calcinurin inhibitors [1]. Therefore, it is 
necessary to search for alternative treatments for patients 
with frequent relapse nephrotic syndrome and SDNS.
Vincristine (VCR) is a vinca alkaloid that has played an 
important role in chemotherapy of malignant diseases for 
3 decades. The beneficial effects of VCR in nephrotic syn-
drome associated with hematological malignancy have 
been noted for many years [2]. But these therapies were 
consisted of a combination of VCR, sterioids and other 
cytotoxic agents and it was unclear whether the remis-
sion of nephrotic syndrome was directly related to VCR. 
Goonasekera et  al. reported two cases of primary focal 
segmental glomerulosclerosis (FSGS) that responded 
to VCR alone [2]. Given those reports, we once treated 
12 SDNS patients with intravenous VCR, all of whom 
had previously completed at least one 8-week course of 
cyclophosphamide but still had frequent relapses. Results 
showed that VCR treatment in a subset of children with 
challenging SDNS could not only relieve proteinuria but 
also reduce relapse frequency. Moreover, side effects 
were minimal in most cases [3]. It indicates that VCR 
may be a valuable alternative treatment for idiopathic 
nephrotic syndrome patients. However, it’s not clear how 
VCR relieves symptoms of nephrotic syndrome.
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Here we demonstrated that VCR could decrease pro-
teinuria in ADR nephropathy rats after 2-week treatment 
and relieve hypoalbuminemia and hypercholesterolemia 
after 4-week treatment. Consistently, VCR rescued podo-
cyte foot process effacement induced by ADR. VCR 
treatment could stabilize actin cytoskeleton structure 
and rescue the morphology of ADR-injured podocytes. 
Molecular analyses indicate that the therapeutic effect 
of VCR may be mediated by inhibiting the pathologi-
cal overexpression of α3β1 integrin and FAK in ADR-
induced nephropathy.
Methods
ADR nephropathy rat model and treatment with VCR
ADR nephropathy was induced in male SD rats weighing 
200 ± 20 g by tail vein injection with single dose of ADR 
(7.5 mg/kg body weight, dissolved in 0.9% NaCl) [4]. As 
normal control group, rats were injected with equal vol-
ume of 0.9% NaCl. Four weeks later, ADR nephropathy 
rats were divided in two groups. One group was injected 
with VCR 0.2  mg/kg body weight twice per week for 
4  weeks. The other group was injected with equal vol-
ume of 0.9% NaCl. Urine was collected from each rat in 
metabolic cage to determine 24  h protein level. It was 
done weekly after ADR injection for the first two weeks 
and then once for every two weeks. Blood samples were 
obtained in chloral hydrate anaesthetized rats at 2, 4 and 
8  weeks after ADR injection. Plasma was extracted for 
serum albumin and cholesterol measurement.
Podocyte cell culture
Immortalized mouse podocyte cell line was kindly pro-
vided by Professor Jianghua Chen (The First Affiliated 
Hospital of Zhejiang University, School of Medicine). 
The immortalized podocytes were cultured for 5  days 
at 33  °C in 5% CO2 under permissive condition [RPMI 
1640 (Sigma) with 10% fetal bovine serum (Gibco), 10U/
ml of recombinant mouse γ-interferon (Peprotech) and 
100U/ml penicillin/streptomycin (Gibco) on type I colla-
gen (Sigma)-coated BD dishes]. They were subsequently 
cultured at 37  °C in 5% CO2 under restrictive condition 
(permissive condition without γ-IFN) to induce differen-
tiation. It took 12–14 days to induce differentiation. After 
podocytes were well-differentiated, they were incubated 
with 0.5  µM ADR to induce cell injury. For VCR treat-
ment group, 5 nM VCR was added 1 h after ADR injury. 
Cells were further cultured for 24 h before the following 
processes.
F‑actin immunofluoresence staining
100 nM working stock of Actin-stain™ 488 phalloidin was 
prepared by diluting 3.5 μl of 14 μM labeled stock phal-
loidin (Cytoskeleton) into 500 μl of PBS. Cells were gently 
washed by PBS after removing culture media at room 
temperature (RT). After 3.7% paraformaldehyde (PFA) 
fixation, cells were rinsed once with PBS and permeabi-
lized by 0.5% Triton X-100/PBS. Cells were rinsed once 
with PBS and then 100 nM Actin-stain™ 488 phalloidin 
was incubated with cells at RT in dark for 30 min. After 
washing three times in PBS, cells were counter-stained 
by DAPI. Images were obtained with DM6000 upright 
microscope (Leica). Fifty high magnification fields from 
each sample were randomly chosen for the measurement 
of cell area and actin fiber number. All the analyses were 
done with Image-Pro Plus. Three separate experiments 
for each group were analyzed.
Quantitative PCR
Total RNA was extracted from the podocytes and kidney 
cortex with Trizol (Invitrogen). 1ug total RNA from each 
sample was reverse transcribed with PrimeScript RT Kit 
(TaKaRa) to synthesize cDNA. Next, 1ul cDNA was used 
for PCR amplification with SYBR Green PCR Master Mix 
(TaKaRa). Reactions were performed on a 7900HT Fast 
Realtime PCR system (ABI). Gapdh was used as inter-
nal normalizer for all the examined genes. At least three 
samples from each group were used for qPCR analysis. 
Primers were designed using the Primer Express software 
(Primer Premier 5.0) based on the Gene Bank accession 
numbers. Primer sequences are:
Gapdh: 5′-CTCATGACCACAGTCCATGC; 5′-CACA 
ATTGGGGGTAGGAACAC; Podocin: 5′-ACCTTTC 
CATGAGGTGGTAAC; 5′-CTGGATGGCTTTGGAC 
AC Nephrin: 5′-CTTGTTGTCCGATTTGCCCC; 5′-CC 
TGGGCTGCAGACACATTA; Synaptopodin: 5′-GCTG 
GAGCTTTGGGCCG; 5′-GTTGAAGAGCTGGACCCC 
TC; Podocalyxin: 5′-TACATCCAAACCGACAGGCA; 
5′-GGCTGTAGTGGTGTGGAGAC; FAK: 5′-ATACA 
CCATGCCCTCAACCAG; 5′-GGTCAAACTGGCGCA 
TTGTT α3-integrin: 5′-ATCCACAGCAATGGGTCC 




Podocytes and kidney cortex were lysed with RIPA Lysis 
Buffer (Beyotime) supplemented with protease inhibi-
tor (Sigma) and phosphatase inhibitor (Roche). After 
determination of protein concentration with BCA pro-
tein assay kit (Bio-Rad), 20  µg protein per sample were 
denatured by boiling at 96 °C for 5 min in sample buffer. 
Equivalent amounts of protein were loaded and electro-
phoresed in SDS-PAGE gels. After electrophoresis, gels 
were transferred to nitrocellulose (NC) filter membranes. 
Next, membranes were blocked with mouse Anti-FAK 
(BD Transduction) or anti-phospho-FAK (Tyr397, 
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Millipore) for 2  h. After washing with PBS, membranes 
were incubated with IRDye 800-conjugated goat anti-
rabbit IgG secondary antibody (Rockland) for half an 
hour. Immunoreactive bands were visualized with a Licor 
Odyssey Infrared Imaging System (LI-COR Biosciences).
Histology
Rats were anaesthetized by chloral hydrate and were sac-
rificed by cervical vertebrae. Kidneys were removed from 
the bodies. The kidney cortex were isolated and fixed in 
10% neutral buffered formalin for hematoxylin and eosin 
staining or fixed in 2.5% glutaraldehyde for electron 
microscopy.
Statistical analysis
Results were analyzed for statistically significant differ-
ences using SPSS 16.0 software. Data were presented as 
mean ±  standard deviation (SD) and tested by one-way 
ANOVA. p < 0.05 were considered significantly.
Results
VCR ameliorates symptoms of ADR‑induced nephropathy 
and rescues foot process effacement
As previously shown [3], VCR has been used to treat SDNS 
patients. To understand how VCR works, we first tested 
whether VCR could treat ADR-induced nephropathy in rat. 
According to the established protocol [4], we treated SD 
rats with 7.5 mg/kg body weight ADR to induce nephrop-
athy. One week after injection, treated rats had already 
shown significant urine protein (Fig. 1a). The level of 24 h 
urine protein rapidly increased at the second week (Fig. 1a). 
Its level reached peak at the sixth week and was maintained 
at the high level from then on (Fig. 1a). On the other hand, 
serum albumin level significantly decreased while serum 
cholesterol level significantly increased at all the time 
points after ADR injection (Fig.  1b, c). Furthermore, we 
examined the ultrastructural change of kidney cortex under 
electron microscope. Effacement of glomerular podocyte 
foot processes was obvious at 4 weeks after ADR injection 
(arrows in Fig.  2b) and became more extensive 4  weeks 
later (arrow in Fig.  2c). HE staining of renal sections at 
4  weeks after ADR treatment didn’t reveal any abnormal 
change (Fig. 2b). However, HE staining of renal sections at 
8 weeks after ADR treatment showed that glomeruli devel-
oped very mild histological changes such as mesangial 
matrix expansion (black arrow in Fig. 3c) and cell infiltra-
tion in interstitial area (green arrow in Fig. 3c). These data 
indicate successful establishment of MCNS model.  
Starting from 4 weeks after ADR injection, rats in VCR 
treatment group were administrated with 0.2 mg/kg body 
weight VCR, which was converted from clinical dosage 
1  mg/m2 according to dose conversion between human 
and rat. At the beginning of VCR treatment, there was no 
difference in 24 h urine protein level between ADR and 
VCR group (Fig.  1a). However, 24  h urine protein level 
decreased significantly after two-week VCR treatment 
and continued to decrease afterwards (Fig. 1a). Consist-
ently, both serum albumin and cholesterol levels were 
recovered to normal ranges after 4  weeks’ treatment 
(Fig.  1b, c). Ultrastructurally, the majority of podocyte 
foot processes reappeared after 4-week VCR treatment 
(Fig.  2d). On cellular level, mesangial matrix deposition 
and cell infiltration in VCR treatment group were also 
attenuated (Fig.  3d). These data indicates that VCR can 
rescue effacement of podocyte foot process to ameliorate 
ADR-induced nephropathy.
Fig. 1 VCR mitigates ADR-induced nephropathy. a Line chart of 24 h 
urine protein. b Line chart of serum albumin level. c Line chart of 
serum cholestoral level. Data are presented as Mean ± SD. *p < 0.05, 
comparison within each group. #p < 0.05, comparison between ADR 
and ADR + VCR groups
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Vincristine stabilizes actin cytoskeleton to maintain 
podocyte morphology in ADR‑injured podocytes
Podocytes are highly differentiated kidney cells playing 
an important role in maintaining the glomerular filtra-
tion barrier. Renal disorders that present with proteinuria 
are usually associated with marked foot process efface-
ment of podocytes. Intact actin cytoskeleton is essential 
to maintain the normal physiology and unique morphol-
ogy of podocyte. ADR directly induces actin fiber depo-
lymerization of podocyte and thereby disrupt its normal 
function. To understand the therapeutic mechanism of 
VCR, we first examined the effect of VCR on the actin 
cytoskeleton organization. Normally, well-differenti-
ated podocytes have an enlarged polygonal shape with 
non-polarized phenotype in culture and a dense mesh-
work of linear actin fibers span the entire cell (Fig.  4a). 
As reported before [5], treatment with 0.5 μM ADR for 
24 h disrupted the normal morphology of podocytes. Cell 
shrank to spindle-like shape and cytoplasmic actin fibers 
were diminished (Fig. 4b).
VCR functions as an antimicrotubule agent and blocks 
cell mitosis at high concentration (≥40 nM) [6]. Since the 
dosage used for nephrotic treatment is much lower than 
that for cancer treatment, we first tested the effect of VCR 
on cultured podocytes at lower concentrations (1, 2, 5, 10 
and 20 nM). We found that treatment with 1, 2 or 5 nM 
VCR for 24 h didn’t have any adverse effect on podocyte 
actin fiber and microtubule cytoskeleton (Fig. 4c and data 
not shown). Hence, we applied 5  nM VCR to test VCR 
effect on ADR injured podocyts. Indeed, 5  nM VCR 
treatment 1 h after ADR injury could stabilize actin fib-
ers and maintain actin cytoskeleton distribution, thereby 
preventing the shrinkage of podocytes, (Fig.  4d). Quan-
titative measurements indicated that both the average 
area and actin fiber number of podocyte decreased sig-
nificantly (p < 0.05) in ADR injured podocytes compared 
with the untreated podocytes, while there was no sig-
nificant difference (p > 0.05) between the untreated and 
ADR  +  VCR groups (Fig.  4e, f ). These results demon-
strate that a low concentration level of VCR can rescue 
ADR-induced podocyte defect through stabilizing actin 
fiber formation.
VCR reduces pathological overexpression of α3β1 integrin 
and FAK in ADR‑induced nephropathy
To further investigate how VCR alleviates actin cytoskel-
eton disorganization in ADR-injured podocyte, we exam-
ined the expression of glomerular filtration barrier key 
components. Integrin-mediated outside-in signaling ini-
tiated by impairment of podocyte-GBM connections is 
Fig. 2 VCR rescues ADR-induced foot process effacement of podocytes. a–d EM images of podocytes. a Slit-like foot processes (arrows) in control 
group. b The majority of foot processes are fused with each other (arrows) after 4-week ADR treatment. c Fused foot processes of podocytes form a 
flat sheet (arrow) to wrap around capillary vessel after 8-week ADR treatment. d Slit-like foot processes (arrow) reappear after 4-week VCR treatment
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one of the mechanisms causing foot process effacement 
and actin cytoskeleton disorganization [7]. α3β1 integ-
rin and FAK are critical in this route [7, 8]. Quantitative 
PCR showed that α3β1 integrin expression levels in ADR 
nephropathy rats were significantly higher than those in 
control rats (p < 0.05), while VCR treatment significantly 
reduced α3β1 integrin overexpression (p < 0.05) (Fig. 5b). 
Similarly, we noted that FAK mRNA level in both cul-
tured podocytes and rat kidney cortex samples was sig-
nificantly increased after ADR injury (p  <  0.05) and 
VCR treatment could significantly reduce FAK expres-
sion level (p  <  0.05) (Fig.  5a, b). Consistently, we found 
that FAK protein level was also significantly increased in 
ADR-induced nephropathic rat kidneys (p  <  0.05) and 
VCR treatment could rescue the pathological overex-
pression of FAK (p < 0.05) (Fig. 5c, d). The key event in 
FAK activation is the phosphorylation of Tyr397, which is 
required for Src binding and necessary for actin cytoskel-
eton remodeling [7]. However, we didn’t find the elevated 
FAK phosphorylation level was significantly rescued by 
VCR treatment (Fig.  5d). In addition, VCR treatment 
didn’t rescue ADR-induced expression changes for other 
critical regulators of actin dynamics, such as podocin, 
nephrin, synaptopodin and podocalyxin, both in podo-
cyte and rat kidney cortex (data not shown). These data 
suggest that the therapeutical effect of VCR on actin fiber 
organization may be mediated through reducing patho-
logical overexpression of α3β1 integrin and FAK.
Discussion
VCR is a well-known antimicrotubule agent that induces 
tubulin self-association into coiled spiral aggregates to 
prevent microtubule assembly and therefore block cell 
mitosis [6]. Hence, it is widely used to treat human can-
cers [6]. Its beneficial effect on nephrotic syndrome of 
leukemia patients prompted nephrologists to use VCR as 
an alternative treatment for nephrotic syndrome [3]. But 
how VCR relieves nephrotic syndrome is unclear.
Nephrotic disorders with proteinuria are usually 
caused by marked foot process effacement of podocytes 
due to actin cytoskeletal disruption [7]. Indeed, we find 
that VCR can stabilize actin cytoskeleton in ADR-injured 
podocyte at a low dosage that doesn’t disrupt micro-
tubules. It indicates that VCR has additional effect on 
cytoskeletons other than microtubule disruption. Inter-
estingly, studies on vincristine resistance in malignant 
tumors show that expression changes in genes encod-
ing actin cytoskeleton components are associated with 
the intrinsic and acquired VCR resistance [9], suggest-
ing a complicated interaction between VCR and actin 
cytoskeleton. Here, we provide the first evidence indicat-
ing that a low concentration of VCR can stabilize actin 
Fig. 3 Histological change of glomeruli. a–d HE staining of kidney section. a Control. b Four-week ADR treatment group. c A slight mesangial 
matrix deposition (black arrow) and interstitial cell infiltration (green arrow) in glomeruli at 8-week ADR treatment group. d ADR and VCR treatment 
group. Scale bar 50 µm
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fibers, although it is unclear whether VCR can directly 
bind actin fibers or not.
Actin cytoskeleton connects to extracellular matrix 
through focal adhesion in foot processes, which consti-
tutes an integral component of the glomerular filtration 
barrier [7]. The maintenance and remodeling of these 
structures are regulated by integrin outside-in signal-
ing modulated by FAK [8]. Podocyte FAK deletion or 
inhibition of FAK activation protect against proteinu-
ria and foot process effacement induced by glomerular 
injury [8]. Our data suggest that the actin fiber-stabiliz-
ing effect of VCR may be mediated by suppressing over-
expression of α3β1 integrin and FAK in both in  vitro 
and in  vivo models. Interestingly, we didn’t note that 
the level of activated form FAK Y397 was significantly 
reduced after VCR treatment. It indicates that the 
Fig. 4 VCR alleviates ADR-induced disorganization of actin cytoskeleton. a–d Fluorescence microscope images of podocytes stained with Alexa 
488 conjugated Phalloidin. a Well-organized linear actin fibers in control podocyte. b ADR treatment reduces the cell size of podocyte and dimin-
ished cytoplasmic actin fibers (arrow). c VCR treatment alone doesn’t change actin cytoskeleton distribution. d ADR-induced cellular changes are 
rescued by VCR treatment. e Quantitative comparison of cell size among different groups. f Quantitative comparison of actin fiber number among 
different groups. Data are presented as Mean ± SD. *p < 0.05
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reduced FAK expression level, independent of FAK 
Y397 activation, is sufficient to alleviate proteinuria and 
foot process effacement. The segregation of FAK over-
expression and FAK Y397 phosphorylation is also noted 
in the activation of cancer cell migration [10]. Our 
data provide novel insight into the complexity of FAK 
activation and downstream effect during the pathogene-
sis of podocyte injury, which requires further investiga-
tion. Further clarification of the therapeutic mechanism 
of VCR would help attract more attention to use it as a 
cheap and effective alternative treatment for nephrotic 
syndrome.
Fig. 5 VCR represses ADR-induced overexpression of α3β1 integrin and FAK. a qPCR analysis of α3β1 integrin and FAK expression in podocytes. 
b qPCR analysis of α3β1 integrin and FAK expression in kidneys. c Western blot analysis of FAK and phospho-FAK in kidneys. d Quantification of FAK 
and phospho-FAK levels. Data are presented as Mean ± SD. *p < 0.05
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